<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01310322</url>
  </required_header>
  <id_info>
    <org_study_id>D2340C00008</org_study_id>
    <nct_id>NCT01310322</nct_id>
  </id_info>
  <brief_title>A Study in Healthy Subjects and Mild Asthmatics to Investigate Pharmacokinetics of AZD5423 When Administered in Different Ways</brief_title>
  <official_title>An Open, Partly Randomised, Four-way Cross-over Study in Healthy Subjects and in Patients With Mild Allergic Asthma to Investigate the Bioavailability and Basic Pharmacokinetics of a Single Dose of AZD5423 When Administered Intravenously, Orally, Inhaled Via SPIRA Nebuliser or Inhaled Via I-neb® AAD Systems</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <brief_summary>
    <textblock>
      A study in healthy subjects and mild asthmatics to investigate Pharmacokinetics of AZD5423
      when administered in different ways.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2011</start_date>
  <completion_date type="Actual">October 2011</completion_date>
  <primary_completion_date type="Actual">October 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics of AZD5423 measured by: Absolute bioavailability (F)</measure>
    <time_frame>Pharmacokinetic (PK) sampling will be performed day 1 to day 5 for each treatment period</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics of AZD5423 measured by: Pulmonary bioavailability (Fpulmonary)</measure>
    <time_frame>Pharmacokinetic (PK) sampling will be performed day 1 to day 5 for each treatment period</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics of AZD5423 measured by: Oral bioavailability after inhaled treatments (Foral)</measure>
    <time_frame>Pharmacokinetic (PK) sampling will be performed day 1 to day 5 for each treatment period</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics of AZD5423 measured by: Area under the plasma concentration-time curve from time zero to infinity (AUC).</measure>
    <time_frame>Pharmacokinetic (PK) sampling will be performed day 1 to day 5 for each treatment period</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To compare the pharmacokinetics between healthy subjects and asthma patients and estimate the basic pharmacokinetic parameters of AZD5423 by measuring e.g. maximum plasma concentration, Cmax</measure>
    <time_frame>Pharmacokinetic (PK) sampling will be performed day 1 to day 5 for each treatment period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the safety and tolerability of AZD5423 measured by adverse events, laboratory variables, physical examination, electrocardiograms, blood pressure and pulse, and spirometry.</measure>
    <time_frame>From screening to follow-up</time_frame>
    <description>To evaluate the safety and tolerability of AZD5423 measured by (Adverse events) (Laboratory variables) (Physical examination) (Electrocardiograms) (blood pressure and pulse) (Spirometry)</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Healthy</condition>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AZD5423 iv</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AZD5423 inhalation, Spira</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AZD5423 inhalation I-neb</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AZD5423 oral</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD5423</intervention_name>
    <description>solution for injection, administered as intravenous infusion Corr to total dose of 250µg AZD5423</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD5423</intervention_name>
    <description>nebuliser suspension, inhaled via Spira, corr to approximately 300 µg lung deposited dose AZD5423</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD5423</intervention_name>
    <description>nebuliser suspension, inhaled via I-neb, corr to approximately 300 µg lung deposited dose AZD5423</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD5423</intervention_name>
    <description>nebuliser suspension to be administered orally, corr to a total dose of 1200 µg AZD5423</description>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male healthy subjects and male asthma patients aged 18 to 45 years (inclusive)

          -  Have a body mass index (BMI) between 18 and 30 kg/m2 (inclusive and rounding allowed)
             and weight between 50 and 100 kg (inclusive)

          -  Be able to inhale from the SPIRA nebuliser and I-neb® according to the provided
             instructions

          -  Asthma patients should fulfil the following criteria: Pre-bronchodilator forced
             expiratory volume at 1 second (FEV1) ≥70% of predicted normal value

          -  Asthma diagnosis according to GINA guidelines with a history of episodic wheeze and
             shortness of breath

        Exclusion Criteria:

          -  History of any clinically significant disease or disorder

          -  Any clinically relevant abnormal findings

          -  Current smokers

          -  Asthma patients: Worsening of asthma or respiratory infection within 6 weeks before
             screening

          -  Asthma patients: Use of inhaled, nasal, oral, rectal or parenteral corticosteroids
             within 30 days before first administration of investigational product and during the
             study
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Darren Wilbraham, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Quintiles Drug Research Unit at Guy's Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Unit</name>
      <address>
        <city>London</city>
        <zip>SE1 1YR</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&amp;studyid=1257&amp;filename=D2340C00008.pdf</url>
    <description>CSR Synopsis</description>
  </link>
  <verification_date>January 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 17, 2011</study_first_submitted>
  <study_first_submitted_qc>March 7, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 8, 2011</study_first_posted>
  <last_update_submitted>January 13, 2015</last_update_submitted>
  <last_update_submitted_qc>January 13, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 14, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Phase I</keyword>
  <keyword>Healthy male volunteers</keyword>
  <keyword>mild asthmatics</keyword>
  <keyword>pharmacokinetics</keyword>
  <keyword>Bioavailability and AUC</keyword>
  <keyword>Level of AZD5423 in your blood</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

